Cardiac Optogenetics: Enhancement by All-trans-Retinal. ↗
Yu J, Chen K, Lucero RV, Ambrosi CM, Entcheva E.
Inte granskat av ActiQs. Detta är en automatiskt skapad sammanställning.
Vad undersöktes?
- Hur undersöktes det?
- virally-transduced (Ad-ChR2(H134R)-eYFP) light-sensitive cardiac syncytium in vitro
- Vilka undersöktes?
- cardiomyocytes
- Vilken ämnesform?
- All-trans-Retinal (ATR)
- Vilken mängd användes?
- ≤2 μM
- Hur länge pågick studien?
- Ingen uppgift i sammanställningen
Studieuppgifterna återges som originalcitat. Uppgifter som saknas här kan finnas i originalutdraget.
Vad kom studien fram till? · Utdrag 1
Författarna rapporterar att tillsats av all-trans-retinal (ATR) i koncentrationer ≤2 μM förbättrade överlevnaden hos cardiomyocyter, medan koncentrationer >4 μM var toxiska.
Vad behöver resultatet vägas mot?
Underlaget omfattar endast utvalda artikelstycken; någon samlad bedömning kan inte göras.
Läs de originalstycken som sammanställningen bygger på
AbstractAll-trans-Retinal (ATR) is a photosensitizer, serving as the chromophore for depolarizing and hyperpolarizing light-sensitive ion channels and pumps (opsins), recently employed as fast optical actuators. In mammalian optogenetic applications (in brain and heart), endogenous ATR availability is not considered a limiting factor, yet it is unclear how ATR modulation may affect the response to optical stimulation. We hypothesized that exogenous ATR may improve light responsiveness of cardiac cells modified by Channelrhodopsin2 (ChR2), hence lowering the optical pacing energy. In virally-transduced (Ad-ChR2(H134R)-eYFP) light-sensitive cardiac syncytium in vitro, ATR supplements ≤2 μM improved cardiomyocyte viability and augmented ChR2 membrane expression several-fold, while >4 μM was toxic. Employing integrated optical actuation (470 nm) and optical mapping, we found that 1–2 μM ATR dramatically reduced optical pacing energy (over 30 times) to several μW/mm2, lowest values reported to date, but also caused action potential prolongation, minor changes in calcium transients and no change in conduction. Theoretical analysis helped explain ATR-caused reduction of optical excitation threshold in cardiomyocytes. We conclude that cardiomyocytes operate at non-saturating retinal levels, and carefully-dosed exogenous ATR can enhance the performance of ChR2 in cardiac cells and yield energy benefits over orders of magnitude for optogenetic stimulation.
Cardiomyocyte viability upon ChR2 expression and ATR treatmentInitial exploration of dosing with exogenous ATR revealed a narrow window of viable concentrations (). ATR supplementation greater than 4 μM was toxic to the cardiomyocytes, regardless of whether they expressed ChR2 or not, and caused complete cell death above 8 μM. However, ATR supplements less than 4 μM appeared to paradoxically improve cell viability even though control samples were quite healthy (): CM with 1 and 2 μM ATR supplements had only 0.1 × and 0.15 × the dead cell amount of CM control (virtually eliminating dead cells, i.e. <2% cell death), p ≪ 0.001 for both, and ChR2-CM with 1 and 2 μM ATR supplements had only 0.38 × and 0.45 × the dead cell amount of CM control, p < 0.01 for both. Intermediate ATR concentration of 4 μM increased cell death compared to cells without ATR supplementation, significant in both CM (1.8 × increase) and ChR-CM cells (4.4 × increase), p < 0.01 for both. Furthermore, it is worth noting that when ATR was present, the ChR2-CM samples had consistently lower viability than the CM samples at the same ATR, even though this was not the case for non-supplemented samples.
Vad undersöktes?
- Hur undersöktes det?
- stable and robust transgene expression (>98%)
- Vilka undersöktes?
- ChR2-CM
- Vilken ämnesform?
- ATR
- Vilken mängd användes?
- 0–4 μM
- Hur länge pågick studien?
- within 48 hours
Studieuppgifterna återges som originalcitat. Uppgifter som saknas här kan finnas i originalutdraget.
Vad kom studien fram till? · Utdrag 2
Författarna rapporterar att tillsats av all-trans-retinal (ATR) i koncentrationsintervallet 0–4 μM ökade ChR2‑uttrycket flera‑fald i ChR2‑expressande cardiomyocyter efter 48 timmar.
Vad behöver resultatet vägas mot?
Underlaget omfattar endast utvalda artikelstycken; någon samlad bedömning kan inte göras.
Läs de originalstycken som sammanställningen bygger på
ChR2 expression with ATR supplementationSince ChR2 stabilization/degradation had been reported to be dependent on ATR availability, we examined ChR2 expression efficiency (by eYFP reporter) in the viable range of ATR supplements, i.e. 0–4 μM. Employing previously reported infection methods without the addition of exogenous ATR, stable and robust transgene expression (>98%) was achieved within 48 hours, (, middle row, first image). We confirmed that in confocal image acquisition of fluorescence (eYFP), greater ATR concentrations did not result in an increase in autofluorescence (, top row). ATR supplementation in ChR2-CM samples led to significant enhancement of ChR2 expression, indicated by the saturation of eYFP fluorescence at the higher doses, despite our attempt to select a gain that maximizes the dynamic range and accommodates all ATR dosing groups (, middle row). Higher resolution images and lowered gain to optimize imaging of the ChR2-CM samples with 4 μM are also shown ( bottom row). Image analysis of eYFP-positive pixels (normalized per cell) showed 3.8 ×, 5 × and 5.9 × increase in ChR2 expression by the addition of 1, 2, and 4 μM ATR compared to ChR2-CM without retinal, p ≪ 0.001 in all cases (). The eYFP fluorescence indicates the total number of expressed channels, including non-functional channelopsins without ATR, therefore the increases shown in represent an upper bound for functional ChR2 channels. We assume that the data indicate a proportionally increasing number of stabilized functional ChR2 channels (fraction of the total reported channels), though increase in actual ChR2 current may be more modest.
Vad undersöktes?
- Hur undersöktes det?
- virally-transduced (Ad-ChR2(H134R)-eYFP) light-sensitive cardiac syncytium in vitro
- Vilka undersöktes?
- cardiomyocytes
- Vilken ämnesform?
- All-trans-Retinal (ATR)
- Vilken mängd användes?
- 1–2 μM
- Hur länge pågick studien?
- Ingen uppgift i sammanställningen
Studieuppgifterna återges som originalcitat. Uppgifter som saknas här kan finnas i originalutdraget.
Vad kom studien fram till? · Utdrag 3
Författarna rapporterar att 1–2 μM all-trans-retinal (ATR) minskade den optiska pacingsenergin med mer än 30‑fald i ett viralt transducerat cardiomyocyt‑syncytium.
Vad behöver resultatet vägas mot?
Underlaget omfattar endast utvalda artikelstycken; någon samlad bedömning kan inte göras.
Läs de originalstycken som sammanställningen bygger på
AbstractAll-trans-Retinal (ATR) is a photosensitizer, serving as the chromophore for depolarizing and hyperpolarizing light-sensitive ion channels and pumps (opsins), recently employed as fast optical actuators. In mammalian optogenetic applications (in brain and heart), endogenous ATR availability is not considered a limiting factor, yet it is unclear how ATR modulation may affect the response to optical stimulation. We hypothesized that exogenous ATR may improve light responsiveness of cardiac cells modified by Channelrhodopsin2 (ChR2), hence lowering the optical pacing energy. In virally-transduced (Ad-ChR2(H134R)-eYFP) light-sensitive cardiac syncytium in vitro, ATR supplements ≤2 μM improved cardiomyocyte viability and augmented ChR2 membrane expression several-fold, while >4 μM was toxic. Employing integrated optical actuation (470 nm) and optical mapping, we found that 1–2 μM ATR dramatically reduced optical pacing energy (over 30 times) to several μW/mm2, lowest values reported to date, but also caused action potential prolongation, minor changes in calcium transients and no change in conduction. Theoretical analysis helped explain ATR-caused reduction of optical excitation threshold in cardiomyocytes. We conclude that cardiomyocytes operate at non-saturating retinal levels, and carefully-dosed exogenous ATR can enhance the performance of ChR2 in cardiac cells and yield energy benefits over orders of magnitude for optogenetic stimulation.
Vad undersöktes?
- Hur undersöktes det?
- Ingen uppgift i sammanställningen
- Vilka undersöktes?
- ChR2-CM
- Vilken ämnesform?
- ATR
- Vilken mängd användes?
- 1 μM
- Hur länge pågick studien?
- Ingen uppgift i sammanställningen
Studieuppgifterna återges som originalcitat. Uppgifter som saknas här kan finnas i originalutdraget.
Vad kom studien fram till? · Utdrag 4
Författarna rapporterar att tillsats av 1 μM all-trans-retinal (ATR) förlängde actionpotentialens varaktighet (APD80) med 44 % i ChR2‑expressande cardiomyocyter.
Vad behöver resultatet vägas mot?
Underlaget omfattar endast utvalda artikelstycken; någon samlad bedömning kan inte göras.
Läs de originalstycken som sammanställningen bygger på
Functional electrophysiology effects of ChR2 expression and ATR supplementation in cardiomyocytesWe further examined the effects of ATR supplementation on CM electrophysiology by quantifying action potentials, calcium transients, and conduction properties. We compared optically-measured (via Di-4-ANBDQBS) action potential durations (APDs) of ChR2-CM to CM with the same treatment, . At zero ATR, CM and ChR2-CM showed overlapping AP and similar APD80 of 260 ms and 270 ms, respectively; reassuring of the benign nature of the opsin expression and optogenetic activation. Addition of 1 μM ATR significantly prolonged the APD80 in ChR2-CMs by 44% (p < 0.05) compared to ChR2-CM without ATR (). Similarly, at zero ATR, no significant differences were seen in calcium transient morphology between the CM and ChR2-CM groups across the tested conditions (); CTD80 of CM and ChR2-CM were 552 ms and 530 ms, respectively (). Supplementation with ATR of 1, 2, and 4 μM in control CM led to: 13.8% (p < 0.05), 13.3% (p < 0.05), and 4% (n.s.) prolongation of CTD80, respectively. In ChR2-CM samples, exogenous ATR supplementation also led to small but significant prolongation of CTD80 by approximately 10.9%, 11.6%, and non-significant 10% for the same tested concentrations (). Examination of propagation and activation maps for the different ChR2-CM groups () showed that ATR supplementation at 1 and 2 μM yielded smooth and fast propagation with similar CV to ChR2-CM control: 19.1 cm/s, 17.0 cm/s, and 17.0 cm/s for 0, 1, and 2 μM, respectively, while 4 μM resulted in small conduction disturbances (likely due to increased number of dead myocytes) and a drop in CV to 14.7 cm/s (). In control CM, ATR had no effect on conduction velocity.
Vad undersöktes?
- Hur undersöktes det?
- Ingen uppgift i sammanställningen
- Vilka undersöktes?
- cardiomyocytes
- Vilken ämnesform?
- ATR
- Vilken mängd användes?
- up to 2 μM
- Hur länge pågick studien?
- Ingen uppgift i sammanställningen
Studieuppgifterna återges som originalcitat. Uppgifter som saknas här kan finnas i originalutdraget.
Vad kom studien fram till? · Utdrag 5
Författarna rapporterar att låga koncentrationer av all-trans-retinal (ATR) upp till 2 μM förbättrade överlevnaden hos cardiomyocyter, påverkade inte ledningshastigheten och orsakade endast liten förlängning av actionpotentialen.
Vad behöver resultatet vägas mot?
Underlaget omfattar endast utvalda artikelstycken; någon samlad bedömning kan inte göras.
Läs de originalstycken som sammanställningen bygger på
Functional electrophysiology effects of ChR2 expression and ATR supplementation in cardiomyocytesOverall, low concentrations of ATR (up to 2 μM) helped improve survival of cardiomyocytes in standard culturing conditions, did not alter conduction and resulted in significant APD prolongation but only slight prolongation of intracellular calcium transients in the ChR2-expressing cardiomyocytes.
Artikelns licens · ActiQs sammanfattningar och texturval är bearbetningar av källan.